Durvalumab and Oleclumab in Resectable PDAC

Clinical trial NCT06060405 · RECRUITING

Trial details

NCT number: NCT06060405
Sponsor: University Health Network, Toronto
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Pancreatic Ductal Adenocarcinoma

Start date: 2023-11-29
Primary completion: 2026-10-30
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.